Compare XERS & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | TRAX |
|---|---|---|
| Founded | 2005 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2021 | 2026 |
| Metric | XERS | TRAX |
|---|---|---|
| Price | $13.32 | $47.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $12.86 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $32.91 | N/A |
| Revenue Next Year | $23.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $15.69 |
| 52 Week High | $11.42 | $50.17 |
| Indicator | XERS | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 73.52 |
| Support Level | $9.73 | $35.11 |
| Resistance Level | $10.60 | N/A |
| Average True Range (ATR) | 0.48 | 3.04 |
| MACD | -0.09 | 0.87 |
| Stochastic Oscillator | 39.36 | 93.27 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.